PHASE-XS — Clinical trials intelligence

SIGNAL

Secure trials intelligence

1,188 molecules. Access the dashboard with Auth0—Universal Login, SSO, and social connections. Built for teams that need audited access and optional billing-ready flows.

v.01 / 3,178 US Biologics Trials

01 / Key Metrics

AT A GLANCE

No. 01Phase 3

707K+ Enrolled

Total participants enrolled across all tracked trials — the largest segment in late-stage studies.

No. 02Oncology

Top Indication

Leukemia, lymphoma, and solid tumors dominate the trial landscape with 40%+ of all studies.

No. 03mAb

Leading Tech

Monoclonal antibodies represent the dominant technology platform across all phases.

No. 0492.3%

Adherence Rate

Average patient compliance across all tracked trials — a key indicator of protocol feasibility.

Dataset scope

Coverage

3,178 Trials
1,188 Molecules
1,178 Indications

TRIAL LANDSCAPE

Phases

Early Phase 1
Phase 1 – 4
Combined Phases

Technologies

Monoclonal Antibodies
CAR-T / Cell Therapy
ADCs & Biosimilars

MODALITY & REGION

Region

United States
India
United Kingdom
Global Collaborators

02 / Coverage

THERAPEUTIC AREAS

Coverage across oncology, immunology, rare disease, and emerging biologic platforms.

Largest Segment

Oncology

Leukemia, lymphoma, melanoma, and solid tumors — spanning checkpoint inhibitors, ADCs, and CAR-T therapies.

Sample Distribution

Technology Mix

Monoclonal Ab

1851

Not Specified

380

Checkpoint Inh.

178

Stem Cell

152

Immunotherapy

124

Illustrative sample

Autoimmune & Inflammation

Immunology

Monoclonal antibodies and biologics targeting rheumatoid arthritis, lupus, and inflammatory bowel disease.

Orphan Biologics

Rare Disease

Gene therapies and enzyme replacements for rare genetic conditions with small patient populations.

Sample Distribution

Trial Phases

Phase 2945

Phase 1820

Phase 3772

Phase 1 / Phase 2310

+ more

Illustrative sample

Market Access

Biosimilars

Follow-on biologics entering the US market — tracking approval timelines, pricing, and competitive dynamics.

Preventive Biologics

Vaccines

mRNA, viral vector, and recombinant protein vaccine platforms across infectious disease trials.

CNS Biologics

Neurology

Emerging biologics for multiple sclerosis, Alzheimer's, and neurodegenerative conditions.

Trajectory

Trials Started Over Time

Highlight — 2009 · count: 92

Enrollment

Participants by Phase

Highlight — Phase 2 · value: 75,699

03 / Platform

WHY PHASE-XS ?

01 / EVIDENCE

EVIDENCE DRIVEN

Every insight is grounded in real clinical data — 3,049 trials, rigorously sourced and continuously validated.

02 / MOLECULE

MOLECULE TO MARKET

Track the full lifecycle from early-phase discovery through approval, pricing, and post-market surveillance.

03 / REAL-TIME

REAL-TIME SIGNALS

Competitive intelligence across sponsors, technologies, and therapeutic areas — filterable, sortable, actionable.

04 / PRECISION

PRECISION ANALYTICS

Enrollment forecasts, adherence tracking, and pricing intelligence across 1,246 unique molecules and 1,085 indications.

Credibility & Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.